Studies on troponin elevation and risk of severe disease or death in COVID-19
| Study | Region | Dates of study | Number | Age* | Male (%) | Tn elevation (%) | Arrhythmia (%) | Death (%) | OR of death or severe disease‡ with Tn elevation |
| Huang et al 3 | China | 16 December 2019–2 January 2020 | 41 (with 17.1% censored) | 49 [41–58] | 73.2 | 12.2 | --- | 14.6 | 12.0 [1.2 - 121.8]‡ |
| Zhou et al 22 | China | 29 December 2020–31 January 2020 | 191 | 56 [46–67] | 62.3 | 16.6 | --- | 28.3 | 80.1 [10.3 - 620.4] |
| Wang et al 4 | China | 1 January 2020–28 January 2020 | 138 (with 61.6% censored) | 56 [42–68] | 54.3 | 7.2§ | 16.7 | 4.3 | 14.3 [2.9 - 71.1]‡ |
| Shi et al 7 | China | 20 January 2020–10 February 2020 | 416 (with 76.7% censored) | 64 (21–95)† | 49.3 | 19.7 | --- | 14.1 | 53.2 [11.4 - 248.0] |
| Guo et al 6 | China | 23 January 2020–3 February 2020 | 187 | 59±15 | 48.7 | 27.8 | 16.7 | 23.0 | 15.1 [6.7 - 34.1] |
| Chen et al 86 | China | January 2020–February 2020 | 150 | 59±16 | 56.0 | 14.7 | --- | 7.3 | 28.3 [9.2 - 87.2]‡ |
*Expressed as median [IQR] or mean±SD.
†Expressed as median (range).
‡OR of severe disease with troponin elevation.
§ Acute myocardial injury defined as biomarker above the 99th percentile upper reference limit or new abnormalities in electrocardiography or echocardiography
IQR, interquartile range; OR, odds ratio; SD, standard deviation; Tn, troponin.